19
views
0
recommends
+1 Recommend
2 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Promoción del envejecimiento saludable a través del abordaje de la fragilidad

      editorial

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Related collections

          Most cited references13

          • Record: found
          • Abstract: found
          • Article: not found

          The effect of frailty on survival in patients with COVID-19 (COPE): a multicentre, European, observational cohort study

          Summary Background The COVID-19 pandemic has placed unprecedented strain on health-care systems. Frailty is being used in clinical decision making for patients with COVID-19, yet the prevalence and effect of frailty in people with COVID-19 is not known. In the COVID-19 in Older PEople (COPE) study we aimed to establish the prevalence of frailty in patients with COVID-19 who were admitted to hospital and investigate its association with mortality and duration of hospital stay. Methods This was an observational cohort study conducted at ten hospitals in the UK and one in Italy. All adults (≥18 years) admitted to participating hospitals with COVID-19 were included. Patients with incomplete hospital records were excluded. The study analysed routinely generated hospital data for patients with COVID-19. Frailty was assessed by specialist COVID-19 teams using the clinical frailty scale (CFS) and patients were grouped according to their score (1–2=fit; 3–4=vulnerable, but not frail; 5–6=initial signs of frailty but with some degree of independence; and 7–9=severe or very severe frailty). The primary outcome was in-hospital mortality (time from hospital admission to mortality and day-7 mortality). Findings Between Feb 27, and April 28, 2020, we enrolled 1564 patients with COVID-19. The median age was 74 years (IQR 61–83); 903 (57·7%) were men and 661 (42·3%) were women; 425 (27·2%) had died at data cutoff (April 28, 2020). 772 (49·4%) were classed as frail (CFS 5–8) and 27 (1·7%) were classed as terminally ill (CFS 9). Compared with CFS 1–2, the adjusted hazard ratios for time from hospital admission to death were 1·55 (95% CI 1·00–2·41) for CFS 3–4, 1·83 (1·15–2·91) for CFS 5–6, and 2·39 (1·50–3·81) for CFS 7–9, and adjusted odds ratios for day-7 mortality were 1·22 (95% CI 0·63–2·38) for CFS 3–4, 1·62 (0·81–3·26) for CFS 5–6, and 3·12 (1·56–6·24) for CFS 7–9. Interpretation In a large population of patients admitted to hospital with COVID-19, disease outcomes were better predicted by frailty than either age or comorbidity. Our results support the use of CFS to inform decision making about medical care in adult patients admitted to hospital with COVID-19. Funding None.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Prevalence of frailty at population level in European ADVANTAGE Joint Action Member States: a systematic review and meta-analysis.

            Although frailty is common among community-dwelling older adults, its prevalence in Europe and how this varies between countries is unclear.
              Bookmark
              • Record: found
              • Abstract: not found
              • Book: not found

              Informe mundial sobre el envejecimiento y la salud

              (2015)
                Bookmark

                Author and article information

                Journal
                resp
                Revista Española de Salud Pública
                Rev. Esp. Salud Publica
                Ministerio de Sanidad, Consumo y Bienestar social (Madrid, Madrid, Spain )
                1135-5727
                2173-9110
                2021
                : 95
                : e202106095
                Affiliations
                [2] Madrid orgnameMinisterio de Sanidad orgdiv1Dirección General de Salud Pública orgdiv2Revista Española de Salud Pública España
                [1] Madrid orgnameMinisterio de Sanidad orgdiv1Dirección General de Salud Pública orgdiv2Subdirección General de Promoción, Prevención y Calidad España
                Article
                S1135-57272021000100101 S1135-5727(21)09500000101
                f0baab6e-0206-4f49-8626-a5da69605779

                This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 International License.

                History
                Page count
                Figures: 0, Tables: 0, Equations: 0, References: 14, Pages: 0
                Product

                SciELO Public Health

                Categories
                Editoriales

                Comments

                Comment on this article